News

08

April

TELA Bio® to Present at 18th Annual Needham Healthcare Conference

MALVERN, Pa., April 8, 2019 /PRNewswire/ — TELA Bio®, Inc., a medical technology company leading the development of advanced regenerative medicine solutions for soft tissue reconstruction, today announced that the company will present at the 18th Annual Needham Healthcare Conference to be held April 9-10, 2019 at the Westin Grand Central Hotel in New York City.

Antony Koblish, president and chief executive officer of TELA Bio, will discuss recent commercial growth experienced with OviTex® Reinforced BioScaffolds (RBSs) for use in hernia repair and abdominal wall reconstruction and will provide an update on the company’s product pipeline. The presentation will be held at 8:40am EDT on Wednesday, April 10th.

The Annual Needham Healthcare Conference is a forum for institutional investors and venture capital firms to hear the latest updates from senior management teams of both leading public and private companies in the biotechnology, specialty pharmaceuticals, medical technology & diagnostics and services sectors. For more information visit: https://www.needhamco.com/news-conferences/

About TELA Bio, Inc.

TELA Bio, Inc. is a disruptive medical technology company focused on making advanced regenerative medicine solutions accessible to patients requiring soft tissue reconstruction. The company’s OviTex Reinforced BioScaffolds (RBSs) products, are a natural hernia repair solution, designed to reduce stretch compared to biologics and long-term complications with permanent synthetics. Each configuration is available with either permanent (polypropylene) polymer or resorbable (polyglycolic acid) polymer reinforcing the same biologic material. The OviTex portfolio is supported by high-quality, data-driven science and extensive pre-clinical research that has consistently demonstrated the advantages of an RBS over commercially available products. OviTex RBSs are commercially available in the U.S. and in Europe. The company is collaborating with leading surgeons to drive rapid product development and establish TELA Bio as a leader in soft tissue reconstruction. To learn more about TELA Bio visit http://www.telabio.com.

Investor relations contact
Stuart Henderson
TELA Bio, Inc
484-320-2933
shenderson@telabio.com

Media contact
Adam Daley
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com

SOURCE TELA Bio, Inc.